Known true · enters 31 Dec 2026

Definium Therapeutics reports the topline primary endpoint result of the Voyage Phase 3 trial (NCT06741228) of DT120 in generalized anxiety disorder (either direction).

TRUE on the date of the first public report of the Voyage trial's primary endpoint result: Definium Therapeutics' topline press release, a results posting on the ClinicalTrials.gov record NCT06741228, or the first peer-reviewed publication that reports the primary result, whichever is first. The result may be positive or negative; the event is about a primary result being reported. An enrollment-complete or last-patient-visit announcement, an interim safety update, a conference abstract without the primary endpoint estimate, or a readout of a different DT120 trial (for example the MDD trial EMERGE) does not count. FALSE at the deadline when no such report is dated by then. Resolution source: Definium Therapeutics' topline press release, with the ClinicalTrials.gov record NCT06741228 as a secondary source.

Resolution source: Definium Therapeutics topline press release; ClinicalTrials.gov record NCT06741228 as secondary source

Readings: 'Their GAD readout, which is expected later this year' is read as: Definium Therapeutics reports the topline primary result of its GAD Phase 3 program in 2026.; The author names that trial in the same post as Voyage, NCT06741228 (the registry bullet coded at owen-2281), so the event is written on that trial.; The claim is about timing, so the event resolves on the first public report of the primary result in either direction, not on whether the endpoint is met.; 'Later this year' = by 31 December 2026 (anchors.json: a year means its last day; origin anchor).; 'Readout' = public report of topline primary-endpoint data. An announcement that the trial has completed or that data are in hand, without the result, does not count.; 'Is expected' is written in the author's own voice with no source cited, so it is read as his expectation (bin B). A coder who reads it as relayed company guidance would code REPORT; that reading is logged here.

upheld (date): Checked for an earlier or later first report. Definium's Q2 2026 release (2026-08-06) says only that Voyage enrollment was complete (214 randomized) and that 'topline data anticipated the week of August 10, 2026', with no result. The topline release (ir.definiumtx.com and Business Wire, 2026-08-12 07:00 ET) reports the primary endpoint: HAM-A change at week 12, -11.6 (DT120 ODT 100 ug) vs -6.2 (placebo), difference -5.4, p<0.0001, and calls it the Company's second Phase 3 readout after Emerge (MDD, June), a different trial. ClinicalTrials.gov NCT06741228 (Definium Therapeutics US; primary completion 2026-07-15; last update 2026-09-02) has no results posted, and no peer-reviewed publication or conference abstract with the primary estimate predates the release; Panorama (September) is a different trial. 2026-08-12 stands.